VT-464

Human CYP17 lyase inhibitor CAS# 1610537-15-9

VT-464

Catalog No. BCC5398----Order now to get a substantial discount!

Product Name & Size Price Stock
VT-464: 5mg $368 In Stock
VT-464: 10mg Please Inquire In Stock
VT-464: 20mg Please Inquire Please Inquire
VT-464: 50mg Please Inquire Please Inquire
VT-464: 100mg Please Inquire Please Inquire
VT-464: 200mg Please Inquire Please Inquire
VT-464: 500mg Please Inquire Please Inquire
VT-464: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of VT-464

Number of papers citing our products

Chemical structure

VT-464

3D structure

Chemical Properties of VT-464

Cas No. 1610537-15-9 SDF Download SDF
PubChem ID 78357816 Appearance Powder
Formula C18H17F4N3O3 M.Wt 399.34
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 50 mg/mL (125.21 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (1S)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol
SMILES CC(C)C(C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O
Standard InChIKey ZBRAJOQFSNYJMF-SFHVURJKSA-N
Standard InChI InChI=1S/C18H17F4N3O3/c1-9(2)18(26,15-8-23-25-24-15)12-4-3-10-6-13(27-16(19)20)14(28-17(21)22)7-11(10)5-12/h3-9,16-17,26H,1-2H3,(H,23,24,25)/t18-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

VT-464 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

VT-464 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on VT-464

VT-464 is a reversible, uncompetitive inhibitor of human CYP17 lyase with an IC50 value of 69nM, and also a competitive inhibitor of hydroxylase with an IC50i value of 670nM [1].

VT-464 is a reversible, uncompetitive inhibitor of CYP17 which is is a single protein with two distinct enzyme activities, 17 α-hydroxylase (hydroxylase) and 17, 20-lyase (lyase). Thus VT-464 has shown a reversible, uncompetitive inhibition of CYP17 lyase with a Ki value of 84nM, and a competitive inhibition of hydroxylase with a Ki value of 620nM. In addition, VT-464 has been reported to significantly inhibit to AR transactivation and AR-dependent PSA and NKX3.1 gene transcription in C4-2, C4-2B, MR49C and MR49F cells [1, 2].

References:
[1] Pisle S T, Pressler H M, Troutman S M, et al. Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model[C]//JOURNAL OF CLINICAL ONCOLOGY. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY, 2012, 30(5).
[2] Eisner J R, Abbott D H, Bird I M, et al. VT-464: a novel, selective inhibitor of P450c17 (CYP17)-17, 20 lyase for castration-refractory prostate cancer (CRPC)[C]//JOURNAL OF CLINICAL ONCOLOGY. 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY, 2012, 30(15).

Featured Products
New Products
 

References on VT-464

Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.[Pubmed:27748439]

Sci Rep. 2016 Oct 17;6:35354.

Cytochrome P450 17alpha-hydroxylase/17,20-lyase (CYP17A1) is a validated treatment target for the treatment of metastatic castration-resistant prostate cancer (CRPC). Abiraterone acetate (AA) inhibits both 17alpha-hydroxylase (hydroxylase) and 17,20-lyase (lyase) reactions catalyzed by CYP17A1 and thus depletes androgen biosynthesis. However, coadministration of prednisone is required to suppress the mineralocorticoid excess and cortisol depletion that result from hydroxylase inhibition. VT-464, a nonsteroidal small molecule, selectively inhibits CYP17A1 lyase and therefore does not require prednisone supplementation. Administration of VT-464 in a metastatic CRPC patient presenting with high tumoral expression of both androgen receptor (AR) and CYP17A1, showed significant reduction in the level of both dehydroepiandrosterone (DHEA) and serum PSA. Treatment of a CRPC patient-derived xenograft, MDA-PCa-133 expressing H874Y AR mutant with VT-464, reduced the increase in tumor volume in castrate male mice more than twice as much as the vehicle (P < 0.05). Mass spectrometry analysis of post-treatment xenograft tumor tissues showed that VT-464 significantly decreased intratumoral androgens but not cortisol. VT-464 also reduced AR signaling more effectively than abiraterone in cultured PCa cells expressing T877A AR mutant. Collectively, this study suggests that VT-464 therapy can effectively treat CRPC and be used in precision medicine based on androgen receptor mutation status.

Description

Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM) that demonstrated both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.

Keywords:

VT-464,1610537-15-9,Natural Products,CYP3A/CYP450, buy VT-464 , VT-464 supplier , purchase VT-464 , VT-464 cost , VT-464 manufacturer , order VT-464 , high purity VT-464

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: